22. Eur J Cancer. 2018 May;95:75-84. doi: 10.1016/j.ejca.2018.02.032. Epub 2018 Apr7.Phase I feasibility study for intrathecal administration of trastuzumab inpatients with HER2 positive breast carcinomatous meningitis.Bonneau C(1), Paintaud G(2), Trédan O(3), Dubot C(4), Desvignes C(2), DierasV(5), Taillibert S(6), Tresca P(7), Turbiez I(7), Li J(8), Passot C(2), MeftiF(9), Mouret-Fourme E(8), Le Rhun E(10), Gutierrez M(11).Author information: (1)Department of Surgery, Institut Curie, Hôpital René Huguenin, 35 Rue Dailly,92210, Saint Cloud, France.(2)Université François-Rabelais de Tours, CNRS, GICC UMR 7292, CHRU de Tours,Service de Pharmacologie-Toxicologie, Tours, France.(3)Department of Oncology, Centre Leon Berard, 28 Prom. Léa et NapoléonBullukian, 69008, Lyon, France.(4)Department of Oncology, Institut Curie, Hôpital René Huguenin, 35 Rue Dailly, 92210, Saint Cloud, France.(5)Department of Oncology, Institut Curie, Hôpital Claudius Regaud, 26 Rue d'Ulm,75005, Paris, France.(6)Department of Neurology Mazarin, Groupe Hospitalier Pitié Salpétrière, 47 bddel'hôpital, 75013, Paris, France; Assistance Publique des Hôpitaux de Paris,Paris, France; Université Pierre et Marie Curie, Paris VI, Paris, France.(7)Department of Clinical Research, Institut Curie, Hôpital René Huguenin, 35 RueDailly, 92210, Saint Cloud, France.(8)Department of Epidemiology, Institut Curie, 26 Rue d'Ulm, 75005, Paris,France.(9)Department of Oncology, Clinique de La Porte Verte, 6 Avenue Maréchal FranchetD'Esperey, 78004, Versailles, France.(10)Lille University, Inserm U1192 PRISM, Villeneuve d'Ascq, France; Breast unit,Department of Medical Oncology, Oscar Lambret Center, 3 Rue Frédéric Combemale,59000, Lille, France; Neuro-oncology, Department of Neurosurgery, UniversityHospital, Lille, France.(11)Department of Oncology, Institut Curie, Hôpital René Huguenin, 35 Rue Dailly,92210, Saint Cloud, France. Electronic address: maya.gutierrez@curie.fr.PURPOSE: Leptomeningeal carcinomatosis (MC) is commonly associated withHER2-positive breast cancer (HER2-BC), with a poor prognosis and no standardised treatment. We conducted a phase I dose-escalation study of intrathecal (IT)administration of trastuzumab in HER2-BC patients with MC to determine themaximum tolerated dose (MTD), which was based on both the achievement of atrastuzumab intra-cerebrospinal fluid concentration close to a conventionaltherapeutic plasma concentration (30 mg/L) and/or dose-limiting toxicity (DLT).METHODS: The protocol planned IT administration of trastuzumab (30 mg, 60 mg,100 mg or 150 mg dose levels) once a week, over the course of at least 4 weeks.Sixteen patients with MC from HER2-BC received IT trastuzumab.Intra-cerebrospinal fluid samples were obtained before each injection forpharmacokinetics.RESULTS: We did not observe DLT of IT trastuzumab. Eleven patients had notoxicity attributed to IT trastuzumab. For 60 mg or higher dose levels, minortoxicities attributed to IT trastuzumab included headache (2 patients), nausea (2patients), vomiting (1 patient), cervical pain (1 patient) and peripheralneuropathy (1 patient). Two patients experienced immediate toxicity includingheadache or vomiting. The mean residual intra-cerebrospinal fluid concentrationof trastuzumab was 27.9 mg/L for the 150 mg dose level. Three patients achieved aclinical response, seven patients had stable disease and four patients hadprogressive disease.CONCLUSIONS: The MTD and recommended phase II weekly dose of IT trastuzumab inpatients with HER2-BC and MC is 150 mg. A phase II trial using this dose regimen in MC from HER2-BC is ongoing.REGISTRATION IDENTIFICATION: ClinicalTrials.gov Identifier: NCT01373710(https://clinicaltrials.gov/ct2/show/NCT01373710?term=trastuzumab+intrathecal&rank=1).Copyright © 2018 Elsevier Ltd. All rights reserved.DOI: 10.1016/j.ejca.2018.02.032 PMID: 29635147 